Xia Men-based China Xia Eye Hospital Group Signs Strategic Clinical Research Collaboration Agreement with Lunan Pharmaceutical to Advance Ophthalmic Innovation

(Source: Xiamen Listed Companies Association)

June 9,Huaxia EyeFormally signed the “Strategic Cooperation Agreement on Clinical Research” with Lunan Pharmaceutical in Xiamen. This collaboration marks a strong alliance between the two parties, establishing a long-term, stable, and mutually beneficial strategic partnership in the clinical research of innovative ophthalmic drugs and medical devices. Together, they will drive innovative development in the biomedical industry within the field of eye health, providing patients with more and better treatment options.

Complementary Advantages

Co-building a New Ecosystem for Clinical Research

The National 14th Five-Year Plan for Bioeconomy Development and other documents explicitly state that the principal role of enterprises in innovation should be strengthened, encouraging deep collaboration between medical institutions and enterprises in clinical research to accelerate the clinical translation and widespread adoption of innovative drugs and medical devices. The partnership between Huaxia Eye and Lunan Pharmaceutical represents a pragmatic measure by a large ophthalmic medical chain group and a domestic innovative pharmaceutical company to respond to the national call for the integration of “industry, academia, research, medicine, and application” and to promote high-quality development in clinical research.

Prior to the signing ceremony, both parties held in-depth discussions.

Li Xiaofeng, a leader of Huaxia Eye Hospital Group, extended a warm welcome to the delegation from Lunan Pharmaceutical. He stated that forming a strategic partnership with Lunan Pharmaceutical, a leading national pharmaceutical enterprise, represents a significant step for Huaxia Eye in deepening the coordinated development of “medical care, education, research, and industry.” Leveraging its nationwide clinical network and research platforms, Huaxia Eye will provide efficient, high-quality support for the clinical evaluation of innovative ophthalmic drugs, jointly explore new diagnostic and therapeutic solutions for eye diseases, and fulfill its mission of bringing light to patients.

Yuan Qingtong, Fujian Regional Director of Lunan New Era Pharmaceutical Co., Ltd., stated that Huaxia Eye is a benchmark enterprise in the field of eye health. This strategic partnership provides a top-tier platform to accelerate the clinical development and market translation of ophthalmic pipeline products. We look forward to working closely to integrate more of Lunan Pharmaceutical’s innovative achievements into Huaxia Eye’s professional service system, thereby realizing a value loop from research to clinical application.

Chen Xia, Deputy Director of the Science and Education Department at Huaxia Eye Hospital Group Co., Ltd., introduced the group’s development history, its national clinical network layout, and the progress in establishing its National Drug Clinical Trial Institution (GCP). Hou Xiaolong, Fujian Regional Academic Manager at Lunan New Era Pharmaceutical Co., Ltd., presented Lunan Pharmaceutical’s R&D achievements and corporate vision in the fields of traditional Chinese medicine modernization, innovative chemical drugs, and general health. Both parties agreed that Huaxia Eye’s nationwide medical service network and abundant clinical resources are highly complementary to Lunan Pharmaceutical’s extensive R&D expertise in areas such as anti-infectives and ophthalmic preparations, offering broad prospects for cooperation.

Deepen Cooperation

Promoting the Synergistic Development of Industry and Clinical Practice

Subsequently, Chen Xia, Deputy Director of the Science and Education Department of Lunan Pharmaceutical Group Corporation, and Zhu Shengdong, Sales Minister for the Fujian Region of Lunan New Era Pharmaceutical Co., Ltd., signed a strategic cooperation agreement on behalf of their respective parties. In accordance with the agreement, both parties will adhere to the principles of “resource sharing, complementary advantages, and mutual benefit and win-win outcomes” to carry out comprehensive and in-depth cooperation. Lunan Pharmaceutical plans to conduct a series of clinical research projects, ranging from Phase I to Phase IV, at Huaxia Eye and its affiliated hospitals, covering innovative drugs and medical devices. Huaxia Eye will provide high-quality clinical research resources, efficient service processes, green channel support, and priority review for relevant projects, jointly enhancing the quality and efficiency of project initiation and implementation.

This strategic cooperation is not merely a project-level alignment, but a joint effort to build an industrial ecosystem. In the future, Lunan Pharmaceutical will actively participate in thematic seminars on clinical trials and research hosted by Huaxia Eye, promoting academic exchange and talent development. Meanwhile, upon approval and market launch, Lunan Pharmaceutical’s relevant research products will enjoy priority recommendation rights at Huaxia Eye under equivalent conditions, helping to extend the benefits of the latest R&D achievements more quickly and broadly to a wide range of patients with eye diseases.

Huaxia Eye is a large national ophthalmic medical chain group in China, integrating medical care, teaching, scientific research, industry, and public welfare. It boasts strong clinical diagnosis and treatment capabilities, an extensive nationwide network layout, and a high-level clinical research platform at the Xiamen Eye Center Affiliated to Xiamen University.

Lunan Pharmaceutical is a well-known comprehensive pharmaceutical group both domestically and internationally, with profound expertise in drug research and development, production, and innovation. The collaboration between the two parties represents a perfect integration of "clinical resources" and "R&D innovation," aiming to streamline the translational pathway from the laboratory to clinical applications, thereby accelerating the validation and market launch of cutting-edge ophthalmic technologies and innovative products.

The signing of this strategic cooperation marks the beginning of a new chapter in the partnership between the two parties. Over the next three years, both sides will build on this foundation, uphold the service philosophy of “patient-centered care,” steadily advance the implementation of various collaborative initiatives, and jointly contribute to enhancing the level of clinical ophthalmic research in China and promoting the development of the eye health industry.

Source: Huaxia Eye Hospital Group Co., Ltd.